SHR-A2009

Phase 2Small molecule

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-A2009 is one of 144 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

143

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Solid TumorActive, not recruiting

Advanced Breast CancerRecruiting

Advanced NSCLCNot yet recruiting

Phase IBNot yet recruiting

Breast CancerPhase 2

Recruiting

Solid TumorPhase 1

Active, not recruiting

Advanced Breast CancerPhase 2

Recruiting

Advanced NSCLCPhase 2

Not yet recruiting

Phase IBPhase 1

Not yet recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

SHR-A2009

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Tricor

JJagotec

Preclinical

1 7

Vfend

PPrism Pharmaceuticals

Preclinical

—8

Ablavar

LLantheus Medical Imaging

Preclinical

2 9

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT05594095

Phase 1Active, not recruiting

Solid Tumor

NCT05114759

Q2 2027

Phase 2Not yet recruiting

Advanced NSCLC

NCT06465238

Q3 2027

Phase 2Recruiting

Advanced Breast Cancer

NCT06649331

Q4 2028

Phase 1Not yet recruiting

Phase IB

NCT07414953

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Completed· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT05394818·19 enrolled

Phase IB1 trial

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07414953·400 enrolled

Advanced NSCLC1 trial

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT06465238·30 enrolled

Breast Cancer1 trial

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

Non-Squamous Non-Small Cell Lung Cancer1 trial

A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 in Combination With Bevacizumab Versus Sacituzumab Tirumotecan in Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07895992·490 enrolled

2 more indications

Advanced Breast Cancer1 trial

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial

Recruiting·FFudan University·Phase 2·NCT06649331·160 enrolled

Solid Tumor1 trial

A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Active, not recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT05114759·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for SHR-A2009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-A2009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-A2009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Suncadia Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-A2009

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Phase IB1 trial

Advanced NSCLC1 trial

Breast Cancer1 trial

Non-Squamous Non-Small Cell Lung Cancer1 trial

Advanced Breast Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News